Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - International Journal …, 2021 - academic.oup.com
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent …
DF Ionescu, DJ Fu, X Qiu, R Lane… - International …, 2021 - search.ebscohost.com
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - International Journal …, 2021 - psycnet.apa.org
Background: Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) …
[PDF][PDF] Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With …
DF Ionescu, DJ Fu, X Qiu, R Lane… - International …, 2021 - pdfs.semanticscholar.org
Background: Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) …
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - The International …, 2021 - europepmc.org
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent …
DF Ionescu, DJ Fu, X Qiu, R Lane… - The international …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
[PDF][PDF] Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - International Journal …, 2021 - academic.oup.com
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
[HTML][HTML] Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With …
DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim… - International Journal …, 2021 - ncbi.nlm.nih.gov
Background Patients with major depressive disorder (MDD) having active suicidal ideation
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …
with intent require immediate treatment. Methods This double-blind study (ASPIRE II) …